enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
Holders of 5% or more of ENGNW
Holders whose latest Schedule 13D or 13G filing reports 5% or more of enGene Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of enGene Therapeutics Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on enGene Therapeutics Inc., newest first.
No Schedule 13D or 13G filings on enGene Therapeutics Inc. are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell enGene Therapeutics Inc. shares.
No Form 144 notices for enGene Therapeutics Inc. are on file.